Kodahl, Annette R5; Zeuthen, Pernille3; Binder, Harald4; Knoop, Ann S5; Ditzel, Henrik J6
1 Oncology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU2 Ditzel group, Department of Molecular Medicine, Det Sundhedsvidenskabelige Fakultet, SDU3 Odense University Hospital4 Johannes Gutenberg-Universität Mainz5 Oncology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU6 Ditzel group, Department of Molecular Medicine, Det Sundhedsvidenskabelige Fakultet, SDU
INTRODUCTION: Circulating microRNAs (miRNAs) exhibit remarkable stability and may serve as biomarkers in several clinical cancer settings. The aim of this study was to investigate changes in the levels of specific circulating miRNA following breast cancer surgery and evaluate whether these alterations were also observed in an independent data set. METHODS: Global miRNA analysis was performed on prospectively collected serum samples from 24 post-menopausal women with estrogen receptor-positive early-stage breast cancer before surgery and 3 weeks after tumor resection using global LNA-based quantitative real-time PCR (qPCR). RESULTS: Numbers of specific miRNAs detected in the samples ranged from 142 to 161, with 107 miRNAs detectable in all samples. After correction for multiple comparisons, 3 circulating miRNAs (miR-338-3p, miR-223 and miR-148a) exhibited significantly lower, and 1 miRNA (miR-107) higher levels in post-operative vs. pre-operative samples (p<0.05). No miRNAs were consistently undetectable in the post-operative samples compared to the pre-operative samples. Subsequently, our findings were compared to a dataset from a comparable patient population analyzed using similar study design and the same qPCR profiling platform, resulting in limited agreement. CONCLUSIONS: A panel of 4 circulating miRNAs exhibited significantly altered levels following radical resection of primary ER+ breast cancers in post-menopausal women. These specific miRNAs may be involved in tumorigenesis and could potentially be used to monitor whether all cancer cells have been removed at surgery and/or, subsequently, whether the patients develop recurrence.